An overview of Phage–Polymyxin Interactions Against Multidrug-Resistant Pseudomonas aeruginosa

Multidrug-resistant (MDR) Pseudomonas aeruginosa causes difficult-to-treat acute and chronic infections, and colistin remains a salvage option limited by nephrotoxicity, heteroresistance and uncertain target-site exposure. Lytic bacteriophages are an independent antibacterial modality, but colistin acts on lipopolysaccharide (LPS), which is also a phage receptor, so the two agents may interact in either direction. This focused narrative review appraises evidence on phage–colistin combinations, emphasising reports from 2024 to October 2026, using four evidence tiers: direct phage–colistin studies, phage studies with other antibiotics, clinical phage studies with background antibiotics, and formulation and pharmacokinetic/pharmacodynamic (PK/PD) literature. Direct in vitro data are heterogeneous: synergy or additivity with colistin was reported for a subset of metallo-β-lactamase-producing isolates, colistin sensitisation occurred in nearly all of nine strains in a 2026 pharmacodynamic study, and phage-first application strengthened synergy for one phage, whereas earlier work showed that colistin can suppress phage lysis and progeny production. Human studies of nebulised and personalised phage therapy support feasibility and safety but cannot attribute effects to colistin because background antibiotics were used. Recovery of infectious phage after storage and aerosolisation emerged as a determinant of potency. We propose critical quality attributes, a PK/PD structure with an explicit interaction term, a six-stage roadmap with go/no-go gates and a minimum reporting checklist. Phage–colistin therapy should be developed as an isolate-matched investigational intervention and should not be assumed to permit lower colistin exposure or improved outcomes without direct validation.

Authors

Institutions

Publication Details

Journal
Zenodo (CERN European Organization for Nuclear Research)
Published
2026-11-18
DOI
https://doi.org/10.5281/zenodo.24332123
Primary Topic
Bacteriophages and microbial interactions
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

An overview of Phage–Polymyxin Interactions Against Multidrug-Resistant Pseudomonas aeruginosa

L. Srimathi, N. Tamilselvi, M. Ragul Ganth, R. Ramya et al.
2 links
Zenodo (CERN European Organization for Nuclear Research)
Bacteriophages and microbial interactions
article

An overview of Phage–Polymyxin Interactions Against Multidrug-Resistant Pseudomonas aeruginosa

L. Srimathi, N. Tamilselvi, M. Ragul Ganth, R. Ramya, D. Manoj, K. Sandhiya, K. Gokul Hari Prasath
article en

Abstract

Multidrug-resistant (MDR) Pseudomonas aeruginosa causes difficult-to-treat acute and chronic infections, and colistin remains a salvage option limited by nephrotoxicity, heteroresistance and uncertain target-site exposure. Lytic bacteriophages are an independent antibacterial modality, but colistin acts on lipopolysaccharide (LPS), which is also a phage receptor, so the two agents may interact in either direction. This focused narrative review appraises evidence on phage–colistin combinations, emphasising reports from 2024 to October 2026, using four evidence tiers: direct phage–colistin studies, phage studies with other antibiotics, clinical phage studies with background antibiotics, and formulation and pharmacokinetic/pharmacodynamic (PK/PD) literature. Direct in vitro data are heterogeneous: synergy or additivity with colistin was reported for a subset of metallo-β-lactamase-producing isolates, colistin sensitisation occurred in nearly all of nine strains in a 2026 pharmacodynamic study, and phage-first application strengthened synergy for one phage, whereas earlier work showed that colistin can suppress phage lysis and progeny production. Human studies of nebulised and personalised phage therapy support feasibility and safety but cannot attribute effects to colistin because background antibiotics were used. Recovery of infectious phage after storage and aerosolisation emerged as a determinant of potency. We propose critical quality attributes, a PK/PD structure with an explicit interaction term, a six-stage roadmap with go/no-go gates and a minimum reporting checklist. Phage–colistin therapy should be developed as an isolate-matched investigational intervention and should not be assumed to permit lower colistin exposure or improved outcomes without direct validation.

Zenodo (CERN European Organization for Nuclear Research)
St. Peter's Institute of Higher Education and Research (IN), Bharath University (IN)
Good health and well-being
Bacteriophages and microbial interactions
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon